Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
54.81 USD
↘ 0.22 (0.39%)🟢PRE MARKET (AS OF 08:36 AM EDT)
🟢Market: OPEN
Open?$55.20
High?$56.11
Low?$53.98
Prev. Close?$55.02
Volume?5.3K
Avg. Volume?4.1M
VWAP?$54.81
Rel. Volume?0.00x
Bid / Ask
Bid?$52.24 × 100
Ask?$58.37 × 100
Spread?$6.13
Midpoint?$55.31
Valuation & Ratios
Market Cap?24.4B
Shares Out?443.3M
Float?406.4M
Float %?94.9%
P/E Ratio?29.48
P/B Ratio?3.54
EPS?$1.87
Dividend?3.02%
Ex-Dividend?N/A

Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $54.81. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 4, 2026.

News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
24.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
39
Momentum?
73
Short Sent.?
74
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.10Grey
Confidence?75%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?3.12%Low
Short Interest?12.7M
Days to Cover?3.3
Free Float406.4M
Avg Daily Volume3.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?2.66Strong
Quick Ratio?2.66Strong
Cash Ratio?1.09Strong
Debt/Equity?1.30Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
47/100
P/E?
Peers
100
S&P
35
29.5FAIR▾
P/B?
Peers
100
S&P
49
3.54FAIR▾
P/S?
Peers
100
S&P
8
9.99HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
19
22.3HIGH▾
EV/Sales?
Peers
100
S&P
5
13.43HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
43
12.0%STRONG▾
ROA?
Peers
50
S&P
38
4.2%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$32.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist